Strategic merger Nova Biomedical has merged with Advanced Instruments to form a larger global life sciences tools provider, indicating expanded capabilities in bioprocessing and clinical diagnostics. This integration signals cross-selling opportunities across combined product lines and a broader customer base in IVD, bioprocessing, and veterinary diagnostics.

Global reach With customers in more than 100 countries and status as the largest privately held IVD company in the U.S., Nova Biomedical offers access to a wide international install base ideal for upsell on advanced analyzers, real-time monitoring solutions, and connected service offerings.

Innovation pipeline Ongoing reinvestment in R&D supports a robust pipeline of high‑performance technologies. This presents sales potential for new platforms, upgrades, and integrated solutions that can be positioned as differentiators in clinical diagnostics and bioprocessing.

Strategic partnerships Recent alliances and acquisitions, including asset integration from NanoCellect and collaboration with Terumo BCT, create co‑selling and bundled solution opportunities, combining hardware with compatible software and workflow enhancements.

Security and reliability Past cybersecurity incident highlights the importance of secure, reliable instrumentation and data management. This creates opportunities to position Nova’s products with strong cybersecurity features, validated QA processes, and service-level agreements that reassure customers in regulated healthcare environments.